The settlement pact paves the way for the introduction of Yesafili, a proposed biosimilar to Eeylea (aflibercept) injection, in the Canadian market, Biocon Biologics said in a regulatory filing.from Moneycontrol Business News https://ift.tt/sDnkf5e
Sunday, March 3, 2024
Biocon Biologics settles patent issue; paves way for launch of biosimilar product in Canada
The settlement pact paves the way for the introduction of Yesafili, a proposed biosimilar to Eeylea (aflibercept) injection, in the Canadian market, Biocon Biologics said in a regulatory filing.from Moneycontrol Business News https://ift.tt/sDnkf5e
Subscribe to:
Post Comments (Atom)
LTIMindtree Q4 Preview: Lower pass-through revenue seen impacting growth marginally
A compilation of estimates suggests the company#39;s Q4 FY24 net profit is projected to decline by 2.2 percent quarter on quarter to Rs 1,1...
-
By BY BEN HUBBARD AND AURELIEN BREEDEN from NYT World https://ift.tt/3oyLkdW >
-
By STEPHANIE SAUL from NYT U.S. https://nyti.ms/2WdcYAk >
No comments:
Post a Comment